PDF file: EURASNET Annual Report 2008

More documents

Recommendations

Info

20. SMEs and Technology TransferWorkpackage description (month 37-54)Workpackage number 20 Starting day or starting event 4 monthParticipant id 1a 2 10b 12a 12c 13 17 22 24Person months 1.5 1 0.5 0.5 0.5 0.5 0.5 4 0.5Objectives• To provide NOE members with advice, information and training that will alert them to commercial opportunities in theirresearch field and enhance their ability to interact successfully with the private sector.• To facilitate the commercial exploitation of reagents, technology and intellectual property in the field of RNA splicingand cognate areas; to forge commercial links between NOE members and existing European companies.• To enhance the commercial viability of a spin-out drug discovery company using RNA splicing factors as drug targets.Description of workResponsibility for coordinating and planning SME & Technology Transfer activities of the network will rest with the HTE-Fund Committee, to be chaired by RL. The committee will provide formal annual reports to the network members inaddition to regular email contact and informal bilateral and multilateral discussions. The committee will initially compriseAL, RL, JT, CB, GTV and JV, who all have prior experience as consultants and/or members of commercial scientificadvisory boards. When the NOE commences, membership of the committee will be expanded to incorporate otherEURASNET members with relevant expertise and to ensure broad representation from across the EU member states. Anindicative list showing prior commercial experience and experience of EURASNET members is provided elsewhere in thisapplication (Section 6.3 d).The committee will review the prior and current commercial experience and commercial activities of all NOE members andwill use this information to establish priorities and develop a commercialization strategy best suited to the NOE.Building on established links between EURASNET members and companies operating in Europe, the HTE-FundCommittee will coordinate negotiations to obtain preferential terms for commercialization of reagents, such as antibodies,expression vectors, probes, cell lines, proteins and cell extracts, that have been generated in the laboratories of EURASNETmembers. This activity will stimulate commercialization by improving access and communication between scientists andcompanies in different EU member states.The HTE-Fund Committee will monitor regularly the requirements of all research projects within the network and reviewthe opportunities for recruiting commercial expertise and technology provision to aid the advancement of research withinthe network. Thus we will establish which commercial sources can supply services needed by Network members, such asDNA sequencing, antibody production, protein expression, microarray analysis, generation of transgenic mice etc., andnegotiate favourable access terms. We will be proactive in seeking opportunities to offer European companies access toexpertise and IP generated within the Network. This will help provide a competitive advantage to European companies byallowing them to expand their range of commercial products, services and technologies.The HTE-Fund Committee will provide a bridge between members of the NOE and industry. The resulting interactions willenhance the transfer of technology, IP and “know-how” from the splicing field into the commercial sector. To ensure thatthe NOE resources are managed as efficiently and productively as possible, we will employ the following strategy. Aninitial two-year phase, corresponding to a ‘proof of concept’ stage, will be established by the NoE; this will be essential tomake the NoE a genuinely attractive partner for future links with the pharmaceutical industry. During the proof of conceptstage several independent projects will be carried out by NOE participants and the results evaluated by the HTE-FundCommittee, in concert with the appointed external consultants, to assess which assay formats and screening targets bestmeet the criteria required for conducting an industrial strength high throughput small molecule screening programme toidentify splicing inhibitors. This work will be coordinated with research activity in WP14 by the HTE-Fund Committee andwill offer all interested NOE members the opportunity to participate in and contribute to the commercial development ofsplicing factor research.277
Deliverables249 Screen at least 10,000 compounds in vitro for inhibitory effects on splicing (month 42).250 Develop a stable cell line for evaluating the effect of chemical inhibitors on pre-mRNA splicing in vivo (month 40).251 Evaluate the mechanism of splicing inhibition by small molecule effectors identified in screening initiative (month 42)359 Develop and/or market commercially at least three new reagents/products for the RNA community (month 54).360 Establish at least two new human stable cell lines for use in analysing pre-mRNA splicing inhibitors in vivo361 Evaluate the mechanism of splicing inhibition by small molecule effectors identified in screening initiative (month 54)362 Screen at least 10,000 compounds for inhibitory effects on splicing either in vitro or in vivo (month 54).278
Page 3 and 4:
TABLE OF CONTENTSA. PERIODIC ACTIVI
Page 5 and 6:
1 PUBLISHABLE EXECUTIVE SUMMARY EUR
Page 7 and 8:
Dr. Davide Gabellini(28) Swiss Inst
Page 9 and 10:
WP7 Molecular characterization of s
Page 11 and 12:
To identify protein-protein interac
Page 13 and 14:
expressed in a particular tissue. T
Page 15 and 16:
Duchenne muscular dystrophy (DMD).
Page 17 and 18:
WP21 Reachout to the broader RNA co
Page 19 and 20:
4.1 TABLE OF MILESTONES JPA MONTH 2
Page 21 and 22:
Numerous plasmids, constructs, extr
Page 23 and 24:
collaboration between EURASNET and
Page 25 and 26:
5.1 WORK PACKAGE REPORTSWork Packag
Page 27 and 28:
• Ongoing regular addition of new
Page 29 and 30:
Work Package 4 The Alternative Spli
Page 31 and 32:
Work Package 6 In silico approaches
Page 33 and 34:
alternative splicing.162 Compare sp
Page 35 and 36:
33 Agreement on pre-mRNA substrates
Page 37 and 38:
its numerous binding sites on both
Page 39 and 40:
Work Package 8 Genome-wide Analyses
Page 41 and 42:
173 Further development of data ana
Page 43 and 44:
Problems and explanations for delay
Page 45 and 46:
eveal that there is a dramatic chan
Page 47 and 48:
Work Package 10 Post-translational
Page 49 and 50:
mutational analysis that led to the
Page 51 and 52:
Isolation of an active step I splic
Page 53 and 54:
FBP11 and 21 with these sequences.
Page 55 and 56:
Similarly to what observed for SF2/
Page 57 and 58:
prp45-113 mutant, which is compatib
Page 59 and 60:
cell lines. In contrast in the pres
Page 61 and 62:
genes with roles in the development
Page 63 and 64:
Structural analyses of several RRMs
Page 65:
Work Package 17 Staff Exchange and
Page 69 and 70:
Barralle's lab, Krämer is acting a
Page 71 and 72:
alternative splicing) and higher ed
Page 73 and 74:
Student Symposium “Decision Makin
Page 75 and 76:
variation and suitability for use w
Page 77 and 78:
Following feedback from members we
Page 79 and 80:
Invited seminars: In addition to me
Page 81 and 82:
Publications 2008Author Title Publi
Page 83 and 84:
Author Title Publication EURASNET P
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Minutes of the General Assembly dec
Page 96 and 97:
241 Evaluate available careerdevelo
Page 98 and 99:
156 The EURASNET memberStamm publis
Page 100 and 101:
y coarse-grained foldingsimulation.
Page 102 and 103:
overexpressor and mutant lines(mont
Page 104 and 105:
machinery with particularrespect to
Page 106 and 107:
alternative splicing, using theEDI
Page 108 and 109:
contemporary findings withinthe EUR
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Licht K, Medenbach J, Lührmann R,K
Page 120 and 121:
Page 122 and 123:
9 TABULAR OVERVIEW OF MAJOR COST IT
Page 124 and 125:
total costs * 18.891,12 52778.60 41
Page 126 and 127:
other (the rest) 48,57 0 56.539,43t
Page 128 and 129:
travel 6.964,91overhead 3.081,07oth
Page 130 and 131:
Participant 1A Type of expenditure
Page 132 and 133:
Participant 1B - Karla Neugebauera)
Page 134 and 135:
Participant 2 - Juan Valcarcela) Wo
Page 136 and 137:
Participant 3 - Stefan Stamma) Work
Page 138 and 139:
Participant 4 - Göran Akusjärvia)
Page 140 and 141:
Participant 5A/B - Peer Bork/Rolf A
Page 142 and 143:
Major cost items• ResearchPersonn
Page 144 and 145:
Participant 7 - Francisco Barallea)
Page 146 and 147:
Francisco Baralle gave a talk to a
Page 148 and 149:
alternative splicing on human disea
Page 150 and 151:
J. Beggs has had frequent contact w
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Participant 12A - Jamal Tazia) Work
Page 158 and 159:
Participant 12B - Bertrand Séraphi
Page 160 and 161:
Participant 12C - Christiane Branla
Page 162 and 163:
Participant 12D - Edouard Bertranda
Page 164 and 165:
Participant 13 - Daniel Schümperli
Page 166 and 167:
Participant 14 - John W. S. Browna)
Page 168 and 169:
Participant 15 - Javier F. Cáceres
Page 170 and 171:
• ResearchPersonnelName WP Person
Page 172 and 173:
MiscellaneousOligonucleotidesUse of
Page 174 and 175:
Major cost items• ResearchConsuma
Page 176 and 177:
Page 178 and 179:
Participant 21 - Angela Krämera) W
Page 180 and 181:
Participant 22 - Angus Lamonda) Wor
Page 182 and 183:
Participant 23 - Chris Smitha) Work
Page 184 and 185:
ChemicalsEnzymesLaboratory supplies
Page 186 and 187:
Participant 26 - Didier Auboeufa) W
Page 188 and 189:
tool for the molecular analysis of
Page 190 and 191:
Participant 29 - Frédéric Allaina
Page 192 and 193:
protein and instead possesses the d
Page 194 and 195:
+ overhead 4.730= total eligible co
Page 196 and 197:
Claudia Tamaro (PhD) has begun work
Page 198 and 199:
ETHZIIMCBUPFSOTON-HGDTOTALJoint Pro
Page 200 and 201:
Direct eligible costs 53.240,48 0,0
Page 202 and 203:
Direct eligible costs 18.720,07 0,0
Page 204 and 205:
13 REPORT ON THE DISTRIBUTION OF TH
Page 206 and 207:
Report on the Distribution of the C
Page 208 and 209:
For most work packages here follows
Page 210 and 211:
pathways (eg, Reactome ).While PAND
Page 212 and 213:
The possible dependence of the effe
Page 214 and 215:
In some treatments or mutants, simi
Page 216 and 217:
Work Package 12: Mis-splicing and D
Page 218 and 219:
acid. Furthermore, using antibodies
Page 220 and 221:
At the 2007 annual meeting in Ile d
Page 222 and 223:
Partner 13 has extensively studied
Page 224 and 225:
inhibitors/modulators of RNA splici
Page 226 and 227:
18 MONTH JPA: WORKPACKAGE TIMECOURS
Page 228 and 229: 15.3 GRAPHICAL PRESENTATION OF WORK
Page 230 and 231: 15.4 TABLE OF MILESTONES (MONTH 37-
Page 232 and 233: 156 The EURASNET memberStamm publis
Page 234 and 235: 194 Bertrand will analyze indetail
Page 236 and 237: 216 Aubeouf and Neugebauer willcoll
Page 238 and 239: 238 Establishing joint PhDcommittee
Page 240 and 241: 283 A unified browser for allknown
Page 242 and 243: 296 Group 12a (Branlant) willuse th
Page 244 and 245: 315 Lamond will use a FLIM-FRET bas
Page 246 and 247: 329 GROUP 7 (F. BARALLE)will contin
Page 248 and 249: 333 GROUP 27 (GABELLINI)will:1) foc
Page 250 and 251: 345 Schümperli’s group isplannin
Page 252 and 253: 366 Quarterly network e-mail atmont
Page 254 and 255: 2. Sharing Resources, Technology an
Page 256 and 257: 5. Ensuring DurabilityWorkpackage d
Page 258 and 259: 7. Molecular Characterization of Sp
Page 260 and 261: 8. Genome-wide Analyses of Splicing
Page 262 and 263: 9. Complexity of Spliceosomal Prote
Page 264 and 265: 202 Srebrow will investigate the ro
Page 266 and 267: 12. Mis-splicing and DiseaseWorkpac
Page 268 and 269: 13. Co-transcriptional Mechanisms o
Page 270 and 271: 14. Chemical Biology and Therapeuti
Page 272 and 273: 15. Development of Enabling Technol
Page 274 and 275: 269 IFMs in 20091. “Alternative a
Page 276 and 277: 18. Career DevelopmentWorkpackage d
Page 280 and 281: 21. Reachout to the Broader RNA Com
Page 282 and 283: 15.7 WORK PACKAGE LIST (MONTHS 37-5
Page 284 and 285: ETHZIIMCBUPFSOTON-HGDTOTALJoint Pro
Page 286 and 287: AMU 5 29 8 42UAAR 5 145 16 1665 29
Page 288 and 289: Joint Programme of Activities RESEA
Page 290 and 291: 60 month period 18 month periodRequ
Page 292 and 293: Integration1. Young Investigator Pr
Page 294 and 295: UCAM-DBIOC 2350,000x1/3 € 50,000x
Page 296: the management team. Audit costs ar
show all

PDF file: EURASNET Annual Report 2008

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?